We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
43 hedge funds and large institutions have $104M invested in Crescent Biopharma in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0% less ownership
Funds ownership: 0.82% → 0.82% (-0%)
10% less capital invested
Capital invested by funds: $115M → $104M (-$11.6M)
14% less funds holding
Funds holding: 50 → 43 (-7)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
43
Holders Change
-7
Holders Change %
-14%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
13
Reduced
11
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$3.15M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.56M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$184K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$47.9K |
